A Single Arm Phase IIa Study (With Combination SRI) to Assess the Safety & Efficacy of AZD4547 in Combination With Either Anastrozole or Letrozole in ER+ Breast Cancer Patients Who Have Progressed on Treatment With Anastrozole or Letrozole

Trial Profile

A Single Arm Phase IIa Study (With Combination SRI) to Assess the Safety & Efficacy of AZD4547 in Combination With Either Anastrozole or Letrozole in ER+ Breast Cancer Patients Who Have Progressed on Treatment With Anastrozole or Letrozole

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2017

At a glance

  • Drugs AZD 4547 (Primary) ; Anastrozole; Exemestane; Letrozole
  • Indications Breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms RADICAL
  • Most Recent Events

    • 17 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
    • 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 04 Apr 2017 Planned End Date changed from 1 Mar 2017 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top